KONINKLIJKE PHILIPS NV (PHI1.DE) Stock Fundamental Analysis

FRA:PHI1 • NL0000009538

26.57 EUR
+0.28 (+1.07%)
Last: Feb 24, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to PHI1. PHI1 was compared to 65 industry peers in the Health Care Equipment & Supplies industry. PHI1 has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, PHI1 is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

3

1. Profitability

1.1 Basic Checks

  • In the past year PHI1 was profitable.
  • PHI1 had a positive operating cash flow in the past year.
  • In multiple years PHI1 reported negative net income over the last 5 years.
  • Of the past 5 years PHI1 4 years had a positive operating cash flow.
PHI1.DE Yearly Net Income VS EBIT VS OCF VS FCFPHI1.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2B 4B

1.2 Ratios

  • The Return On Assets of PHI1 (3.32%) is comparable to the rest of the industry.
  • PHI1 has a Return On Equity (8.17%) which is in line with its industry peers.
  • PHI1 has a Return On Invested Capital (5.16%) which is comparable to the rest of the industry.
  • The Average Return On Invested Capital over the past 3 years for PHI1 is significantly below the industry average of 9.73%.
  • The last Return On Invested Capital (5.16%) for PHI1 is above the 3 year average (3.24%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 3.32%
ROE 8.17%
ROIC 5.16%
ROA(3y)-0.23%
ROA(5y)0.96%
ROE(3y)-0.52%
ROE(5y)1.86%
ROIC(3y)3.24%
ROIC(5y)N/A
PHI1.DE Yearly ROA, ROE, ROICPHI1.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 -10 20

1.3 Margins

  • PHI1's Profit Margin of 5.02% is in line compared to the rest of the industry. PHI1 outperforms 44.62% of its industry peers.
  • PHI1's Profit Margin has declined in the last couple of years.
  • With a Operating Margin value of 7.98%, PHI1 perfoms like the industry average, outperforming 41.54% of the companies in the same industry.
  • In the last couple of years the Operating Margin of PHI1 has declined.
  • Looking at the Gross Margin, with a value of 45.18%, PHI1 is doing worse than 75.38% of the companies in the same industry.
  • PHI1's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 7.98%
PM (TTM) 5.02%
GM 45.18%
OM growth 3YN/A
OM growth 5Y-5.59%
PM growth 3YN/A
PM growth 5Y-6.05%
GM growth 3Y3.66%
GM growth 5Y-0.43%
PHI1.DE Yearly Profit, Operating, Gross MarginsPHI1.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 20 30 40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. Health

2.1 Basic Checks

  • PHI1 has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • The number of shares outstanding for PHI1 has been increased compared to 1 year ago.
  • PHI1 has more shares outstanding than it did 5 years ago.
  • PHI1 has a worse debt/assets ratio than last year.
PHI1.DE Yearly Shares OutstandingPHI1.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M
PHI1.DE Yearly Total Debt VS Total AssetsPHI1.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B

2.2 Solvency

  • The Debt to FCF ratio of PHI1 is 16.37, which is on the high side as it means it would take PHI1, 16.37 years of fcf income to pay off all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 16.37, PHI1 is doing worse than 61.54% of the companies in the same industry.
  • PHI1 has a Debt/Equity ratio of 0.63. This is a neutral value indicating PHI1 is somewhat dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.63, PHI1 is doing worse than 70.77% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.63
Debt/FCF 16.37
Altman-Z N/A
ROIC/WACC0.8
WACC6.44%
PHI1.DE Yearly LT Debt VS Equity VS FCFPHI1.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5B 10B

2.3 Liquidity

  • PHI1 has a Current Ratio of 1.32. This is a normal value and indicates that PHI1 is financially healthy and should not expect problems in meeting its short term obligations.
  • With a Current ratio value of 1.32, PHI1 is not doing good in the industry: 61.54% of the companies in the same industry are doing better.
  • A Quick Ratio of 0.94 indicates that PHI1 may have some problems paying its short term obligations.
  • PHI1's Quick ratio of 0.94 is on the low side compared to the rest of the industry. PHI1 is outperformed by 66.15% of its industry peers.
Industry RankSector Rank
Current Ratio 1.32
Quick Ratio 0.94
PHI1.DE Yearly Current Assets VS Current LiabilitesPHI1.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • PHI1 shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 6.11%.
  • PHI1 shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -6.62% yearly.
  • Looking at the last year, PHI1 shows a decrease in Revenue. The Revenue has decreased by -1.04% in the last year.
  • The Revenue has been growing slightly by 0.59% on average over the past years.
EPS 1Y (TTM)6.11%
EPS 3Y15.66%
EPS 5Y-6.62%
EPS Q2Q%-1.96%
Revenue 1Y (TTM)-1.04%
Revenue growth 3Y0.01%
Revenue growth 5Y0.59%
Sales Q2Q%1.05%

3.2 Future

  • PHI1 is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 8.42% yearly.
  • Based on estimates for the next years, PHI1 will show a small growth in Revenue. The Revenue will grow by 3.77% on average per year.
EPS Next Y3.51%
EPS Next 2Y8.11%
EPS Next 3Y15.73%
EPS Next 5Y8.42%
Revenue Next Year1.71%
Revenue Next 2Y3.03%
Revenue Next 3Y3.53%
Revenue Next 5Y3.77%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
PHI1.DE Yearly Revenue VS EstimatesPHI1.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 5B 10B 15B 20B 25B
PHI1.DE Yearly EPS VS EstimatesPHI1.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0.5 1 1.5 2

More info and screens

Find the best growth stocksShow best growing peers

3

4. Valuation

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 18.07, PHI1 is valued on the expensive side.
  • 76.92% of the companies in the same industry are more expensive than PHI1, based on the Price/Earnings ratio.
  • PHI1's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 26.98.
  • A Price/Forward Earnings ratio of 17.46 indicates a rather expensive valuation of PHI1.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of PHI1 is on the same level as its industry peers.
  • When comparing the Price/Forward Earnings ratio of PHI1 to the average of the S&P500 Index (28.01), we can say PHI1 is valued slightly cheaper.
Industry RankSector Rank
PE 18.07
Fwd PE 17.46
PHI1.DE Price Earnings VS Forward Price EarningsPHI1.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, PHI1 is valued a bit cheaper than the industry average as 69.23% of the companies are valued more expensively.
  • PHI1's Price/Free Cash Flow is on the same level as the industry average.
Industry RankSector Rank
P/FCF 51.79
EV/EBITDA 12.11
PHI1.DE Per share dataPHI1.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • A more expensive valuation may be justified as PHI1's earnings are expected to grow with 15.73% in the coming years.
PEG (NY)5.14
PEG (5Y)N/A
EPS Next 2Y8.11%
EPS Next 3Y15.73%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • PHI1 does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

KONINKLIJKE PHILIPS NV

FRA:PHI1 (2/24/2026, 7:00:00 PM)

26.57

+0.28 (+1.07%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-10
Earnings (Next)05-06
Inst Owners44.83%
Inst Owner ChangeN/A
Ins Owners0.06%
Ins Owner ChangeN/A
Market Cap25.59B
Revenue(TTM)17.83B
Net Income(TTM)895.00M
Analysts73.33
Price Target27.26 (2.6%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0.35
Dividend Growth(5Y)216.55%
DP36.65%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)9.02%
Min EPS beat(2)3.95%
Max EPS beat(2)14.1%
EPS beat(4)4
Avg EPS beat(4)17.83%
Min EPS beat(4)3.95%
Max EPS beat(4)31.04%
EPS beat(8)4
Avg EPS beat(8)2.84%
EPS beat(12)6
Avg EPS beat(12)6.47%
EPS beat(16)7
Avg EPS beat(16)6.93%
Revenue beat(2)0
Avg Revenue beat(2)-1.63%
Min Revenue beat(2)-2.4%
Max Revenue beat(2)-0.86%
Revenue beat(4)0
Avg Revenue beat(4)-1.8%
Min Revenue beat(4)-2.4%
Max Revenue beat(4)-0.86%
Revenue beat(8)0
Avg Revenue beat(8)-2.61%
Revenue beat(12)1
Avg Revenue beat(12)-2.36%
Revenue beat(16)2
Avg Revenue beat(16)-1.72%
PT rev (1m)0.7%
PT rev (3m)-1.42%
EPS NQ rev (1m)-20.3%
EPS NQ rev (3m)-14.31%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.56%
Revenue NQ rev (1m)2.87%
Revenue NQ rev (3m)2.28%
Revenue NY rev (1m)-0.99%
Revenue NY rev (3m)-1.57%
Valuation
Industry RankSector Rank
PE 18.07
Fwd PE 17.46
P/S 1.43
P/FCF 51.79
P/OCF 22.02
P/B 2.33
P/tB N/A
EV/EBITDA 12.11
EPS(TTM)1.47
EY5.53%
EPS(NY)1.52
Fwd EY5.73%
FCF(TTM)0.51
FCFY1.93%
OCF(TTM)1.21
OCFY4.54%
SpS18.52
BVpS11.38
TBVpS-0.92
PEG (NY)5.14
PEG (5Y)N/A
Graham Number19.4
Profitability
Industry RankSector Rank
ROA 3.32%
ROE 8.17%
ROCE 7.33%
ROIC 5.16%
ROICexc 6.02%
ROICexgc 20.88%
OM 7.98%
PM (TTM) 5.02%
GM 45.18%
FCFM 2.77%
ROA(3y)-0.23%
ROA(5y)0.96%
ROE(3y)-0.52%
ROE(5y)1.86%
ROIC(3y)3.24%
ROIC(5y)N/A
ROICexc(3y)3.72%
ROICexc(5y)N/A
ROICexgc(3y)12.84%
ROICexgc(5y)N/A
ROCE(3y)4.62%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5Y-1.31%
ROICexc growth 3YN/A
ROICexc growth 5Y-4.82%
OM growth 3YN/A
OM growth 5Y-5.59%
PM growth 3YN/A
PM growth 5Y-6.05%
GM growth 3Y3.66%
GM growth 5Y-0.43%
F-Score7
Asset Turnover0.66
Health
Industry RankSector Rank
Debt/Equity 0.63
Debt/FCF 16.37
Debt/EBITDA 2.72
Cap/Depr 59.38%
Cap/Sales 3.75%
Interest Coverage 5.63
Cash Conversion 45.59%
Profit Quality 55.2%
Current Ratio 1.32
Quick Ratio 0.94
Altman-Z N/A
F-Score7
WACC6.44%
ROIC/WACC0.8
Cap/Depr(3y)53.03%
Cap/Depr(5y)53.41%
Cap/Sales(3y)3.68%
Cap/Sales(5y)4%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)6.11%
EPS 3Y15.66%
EPS 5Y-6.62%
EPS Q2Q%-1.96%
EPS Next Y3.51%
EPS Next 2Y8.11%
EPS Next 3Y15.73%
EPS Next 5Y8.42%
Revenue 1Y (TTM)-1.04%
Revenue growth 3Y0.01%
Revenue growth 5Y0.59%
Sales Q2Q%1.05%
Revenue Next Year1.71%
Revenue Next 2Y3.03%
Revenue Next 3Y3.53%
Revenue Next 5Y3.77%
EBIT growth 1Y15922.2%
EBIT growth 3YN/A
EBIT growth 5Y-5.03%
EBIT Next Year63.55%
EBIT Next 3YN/A
EBIT Next 5Y17.05%
FCF growth 1Y-43.86%
FCF growth 3YN/A
FCF growth 5Y-22.31%
OCF growth 1Y-25.32%
OCF growth 3YN/A
OCF growth 5Y-15.14%

KONINKLIJKE PHILIPS NV / PHI1.DE FAQ

What is the ChartMill fundamental rating of KONINKLIJKE PHILIPS NV (PHI1.DE) stock?

ChartMill assigns a fundamental rating of 3 / 10 to PHI1.DE.


What is the valuation status for PHI1 stock?

ChartMill assigns a valuation rating of 4 / 10 to KONINKLIJKE PHILIPS NV (PHI1.DE). This can be considered as Fairly Valued.


How profitable is KONINKLIJKE PHILIPS NV (PHI1.DE) stock?

KONINKLIJKE PHILIPS NV (PHI1.DE) has a profitability rating of 3 / 10.


How financially healthy is KONINKLIJKE PHILIPS NV?

The financial health rating of KONINKLIJKE PHILIPS NV (PHI1.DE) is 1 / 10.


Can you provide the dividend sustainability for PHI1 stock?

The dividend rating of KONINKLIJKE PHILIPS NV (PHI1.DE) is 0 / 10 and the dividend payout ratio is 36.65%.